X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PLG0206 is an investigational broad-spectrum, anti-bacterial and anti-biofilm peptide therapeutic currently in clinical development for the treatment of Periprosthetic Joint Infection.
Lead Product(s): PLG0206
Therapeutic Area: Infections and Infectious Diseases Product Name: PLG0206
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
PLG0206 is an investigational, broad-spectrum, anti-biofilm, anti-infective peptide, best-in-class, rapid bactericidal therapeutic currently in clinical development for the treatment of periprosthetic joint infection (PJI).
Lead Product(s): PLG0206
Therapeutic Area: Infections and Infectious Diseases Product Name: PLG0206
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
Results demonstrate that PLG0206 was active against all tested isolates and retained activity against multi-drug resistant (MDR) strains, suggesting that the unique mechanism of action of PLG0206 can overcome the drug-resistance mechanisms found in these MDR strains.
Lead Product(s): PLG0206
Therapeutic Area: Infections and Infectious Diseases Product Name: PLG0206
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2022
Details:
PLG0206 is an investigational, broad-spectrum, non-traditional antibiotic peptide therapeutic for the treatment of PJI. PLG0206 has the potential to rapidly target bacteria and persistent pathogens that produce biofilm and evade conventional antibiotics.
Lead Product(s): PLG0206
Therapeutic Area: Infections and Infectious Diseases Product Name: PLG0206
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
PLG0206 was designed with a unique mechanism of action that allows it to directly address persistent bacterial pathogens within the biofilm that evade standard-of-care antibiotics by targeting and disrupting bacterial membranes to trigger bacterial cell death.
Lead Product(s): PLG0206
Therapeutic Area: Infections and Infectious Diseases Product Name: PLG0206
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 19, 2022
Details:
Peptilogics’ Nautilus™ platform enables in silico predictive peptide design across diverse targets to efficiently access new functional chemical space and custom design therapeutics.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Peptide
Recipient: Orion Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration July 12, 2022
Details:
Poster and oral presentation of PLG0206 showcase broad-spectrum activity against drug-resistant bacteria and its ability to prevent spontaneous mutant growth with a variety of pathogens that cause periprosthetic joint infections (PJI).
Lead Product(s): PLG0206
Therapeutic Area: Infections and Infectious Diseases Product Name: PLG0206
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
PLG0206, is a novel peptide therapy granted orphan drug designation, initially targeted for prosthetic joint infections, an orthopedics indication is best-in-class, broad-spectrum potency targets multi-drug-resistant bacteria with improved resistance profiles.
Lead Product(s): PLG0206
Therapeutic Area: Infections and Infectious Diseases Product Name: PLG0206
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2022
Details:
The award provided by the Cystic Fibrosis Foundation will generate both in vitro and in vivo data about PLG0301 and PLG0206, which may potentially support an Investigational New Drug (IND) application with the FDA for its continued development.
Lead Product(s): PLG0301
Therapeutic Area: Infections and Infectious Diseases Product Name: PLG0301
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Cystic Fibrosis Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding January 05, 2022
Details:
The proceeds of the financing will be used to expand Peptilogics’ computational platform and invest in technologies to improve its drug design engine, as well as accelerate development of a pipeline of peptide therapeutics including the Company’s lead clinical asset, PLG0206.
Lead Product(s): PLG0206
Therapeutic Area: Infections and Infectious Diseases Product Name: PLG0206
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Presight Capital
Deal Size: $35.4 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 21, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
